Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns - 2The 15 Most Powerful Forerunners in Business
- 3Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out
- 4More loons are filling Maine's lakes with their ghostlike calls
- 5HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
- Polar bears are rewiring their own genetics to survive a warming climate
- Kiev declares energy emergency after Russian attacks amid winter cold
- With Obamacare premium hikes, more people opting for no coverage or cheaper plans
- Opening Potential: Self-awareness and Long lasting Learning
- 5 Superstar Couples That Motivate Relationship Objectives
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- Internet Bookkeeping Programming for Consultants
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- At UN climate conference, some activists and scientists want more talk on reforming agriculture
